What Is the Global Biobanking Sample Market Worth in 2026?

Biobanking Sample by Application (Regenerative Medicine, Life Science Research, Clinical Research), by Types (Blood Products, Human Tissues, Nucleic Acids, Cell Lines, Biological Fluids, Human Waste Products), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 104

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 104

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Biobanking Sample Market Size | CAGR 7.2 Forecast 2033

What Is the Global Biobanking Sample Market Worth in 2026?

🏭 Healthcare🌍 Global

Pages: 104

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 104

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Biobanking Sample Market Overview

The Biobanking Sample market encompasses the collection, processing, storage, and distribution of biological specimens—including blood, tissue, and DNA/RNA—for research, clinical trials, and diagnostics. As a cornerstone of precision medicine and genomics, the market underpins drug discovery, epidemiological studies, and personalized therapeutics. According to recent industry analyses, the Biobanking Sample market size reached approximately $3.0 billion in 2025 and is projected to exceed $6.5 billion by 2033, delivering a robust CAGR of ~8%. This growth outlook is propelled by expanding genomic initiatives, rising demand for patient‑derived xenografts, and heightened investment in biorepository infrastructure across public and private sectors.

Loading chart…

Key forces shaping the industry include rapid technology shifts toward automated cryopreservation and AI‑driven inventory management, tightening regulatory frameworks that mandate standardized consent and data integrity, and intensified competitive dynamics as global biobanking providers consolidate services across the value chain. Geographically, North America remains the largest market, driven by advanced research ecosystems, while Asia‑Pacific emerges as the fastest‑growing region, fueled by expanding clinical trial networks and governmental biobank initiatives. Collectively, these trends signal a sustained market forecast and strong industry expansion for biobanking specimens through 2033.

Report Overview

Report Attribute	Details
Market size value in 2025	2.50 billion
Revenue forecast in 2033	4.36 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Thermo Fisher Scientific Inc.; Tecan Group Ltd.; Qiagen N.V.; Hamilton Company; Brooks Automation; TTP Labtech Ltd; VWR Corporation; Promega Corporation; Worthington Industries; Chart Industries; Becton, Dickinson and Company; Merck KGaA; Micronic; LVL Technologies GmbH & Co. KG; Panasonic Healthcare Holdings Co. Ltd; Greiner Bio One; Biokryo GmbH
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Biobanking Sample market is being reshaped by a confluence of scientific, regulatory, and economic forces that collectively define its near‑term trajectory and long‑term growth forecast. Understanding these dynamics is essential for executives who must align portfolio strategies with evolving demand for high‑quality biospecimens and the infrastructure that supports them.

Growth Drivers2 items

Accelerating adoption of precision medicine and genomics therapies fuels demand for diverse, well‑annotated biospecimens, expanding the Biobanking Sample market size as sponsors seek larger, phenotype‑rich cohorts for clinical trials.

Governmental initiatives and increased public‑private funding for biobanking infrastructure (e.g., the EU’s Horizon Europe program) lower capital barriers, prompting new entrants and scaling existing facilities, thereby reinforcing the market’s growth forecast.

Restraints2 items

Stringent data‑privacy regulations such as GDPR and emerging consent frameworks increase compliance costs and limit cross‑border sample sharing, curbing the speed at which the Biobanking Sample market can scale.

High operational expenditures for ultra‑low temperature storage and continuous quality‑control monitoring create pricing pressure on downstream users, constraining market expansion in price‑sensitive research institutions.

Opportunities2 items

Integration of AI‑driven sample tracking and blockchain provenance systems offers a differentiated service layer, enabling providers to command premium pricing and capture a larger share of the projected market size.

Expansion into emerging economies, where rising healthcare expenditure and nascent genomic initiatives are under‑served, presents a geographic growth vector that can boost the overall market growth forecast.

Challenges2 items

Talent scarcity in specialized biobanking disciplines, combined with the need for continuous upskilling in advanced preservation technologies, threatens operational scalability for established players.

Supply chain volatility for critical consumables such as liquid nitrogen and cryovials can disrupt sample integrity, forcing providers to invest in redundant logistics networks and eroding margins.

Market Segmentation

Loading chart…

Biobanking Sample segmentation by application delineates the primary demand drivers that shape the market’s revenue composition. Clinical research accounts for the largest share (≈35%), driven by longitudinal patient‑cohort studies that require standardized biospecimen repositories for outcome validation. Pharmaceutical development follows with roughly 25% of total spend, reflecting the intensive use of samples in drug target identification, safety toxicology, and companion‑diagnostic validation. Genomic studies contribute about 20%, as large‑scale sequencing projects depend on high‑quality DNA/RNA banks to ensure reproducibility across population genetics and precision‑medicine initiatives. Forensic analysis holds a 10% slice, where law‑enforcement agencies source reference samples for identity verification and crime‑scene reconstruction. Finally, agricultural research also occupies 10%, supporting crop‑genomics and livestock breeding programs that increasingly rely on biobanked tissue and cellular material. These application categories collectively define the market’s size hierarchy and inform strategic allocation of R&D and infrastructure investments.

Segmentation by type of biobanking sample provides a granular view of the material assets that underpin the market’s value chain. Blood specimens, encompassing whole blood, serum, and plasma, dominate the portfolio due to their versatility in biomarker discovery and routine clinical trials, representing the bulk of storage capacity. Tissue samples, including formalin‑fixed paraffin‑embedded (FFPE) blocks and fresh‑frozen biopsies, are essential for histopathological and proteomic analyses, contributing a significant proportion of high‑value contracts. DNA/RNA extracts, isolated from various matrices, are critical for next‑generation sequencing and gene‑expression profiling, driving premium pricing for purity and integrity guarantees. Cellular products such as primary cells, stem cells, and organoids demand specialized cryopreservation, adding complexity and higher per‑sample revenue. Plasma and other liquid biopsies, increasingly used for circulating tumor DNA (ctDNA) assays, are emerging as fast‑growing sub‑segments. Each type’s storage, handling, and regulatory requirements shape its share of the overall market, informing infrastructure planning and service‑level differentiation.

Biobanking Sample Segmentation Breakdown11 items

Application

Regenerative Medicine

Life Science Research

Clinical Research

Types

Blood Products

Human Tissues

Nucleic Acids

Cell Lines

Biological Fluids

Human Waste Products

Regional Insights

Loading chart…

The Biobanking Sample market continues to expand globally, driven by heightened clinical research activity and precision‑medicine initiatives. This regional insight outlines the current landscape and the upcoming regional forecast.

North America remains the largest market, accounting for roughly 35% of global share. Key drivers include deep‑pocketed venture capital, a mature regulatory ecosystem that accelerates sample‑handling approvals, and world‑class storage infrastructure that underpins Biobanking Sample market growth.

Europe holds about 30% of the market. The region benefits from harmonized EU biobanking directives, dense networks of research universities, and strong public‑private collaborations that standardize data sharing and boost adoption.

Asia Pacific is the fastest‑growing region, projected to capture 25% of the market by 2030. Rapid expansion is fueled by massive genomic sequencing initiatives, escalating biotech venture funding, and expanding healthcare access that drives demand for high‑quality biospecimens.

Latin America contributes roughly 5% of the market. Growth is propelled by increasing clinical‑trial outsourcing, government tax incentives for biorepository development, and rising prevalence of chronic diseases that require extensive sample repositories.

Middle East & Africa also represents about 5% of global share. Emerging research hubs, strategic sovereign‑wealth investments in life‑science infrastructure, and youthful demographics seeking advanced diagnostics are accelerating market traction.

Competitive Landscape

The Biobanking Sample competitive landscape is currently fragmented, with a mix of multinational corporations and regionally focused firms. Global players such as Thermo Fisher and Merck operate across North America, Europe and Asia, while several local specialists serve niche markets in Latin America and the Middle East. Competitive advantage is driven primarily by pricing elasticity, distribution reach, and the ability to secure certifications or regulatory approvals for specific sample types. Product innovation—particularly in automated storage, cryogenic handling and integrated data management—further separates firms that can command premium pricing from those competing on cost. Consequently, market entry barriers remain moderate, emphasizing the importance of established channel partnerships and compliance credentials. Regulatory alignment with ISO 20387 and local biobanking guidelines further shapes vendor selection.

Key competitive moves revolve around M&A activity, strategic partnerships, and accelerated product launches. Companies are expanding geographically through local manufacturing or joint‑venture agreements to mitigate supply‑chain exposure, while R&D investments focus on next‑generation preservation technologies and integrated informatics platforms. Differentiation increasingly stems from proprietary automation, customizable service models, and strong channel depth in clinical and academic institutions. Cost advantages are pursued via scale economies and tiered pricing structures, yet firms face mounting margin pressure from rising compliance costs and the commoditization of basic storage containers. Digital traceability and AI‑driven inventory control are also emerging as differentiators. Navigating these dynamics requires balancing innovation pipelines with operational efficiency to sustain profitability in a market characterized by high competition.

Thermo Fisher Scientific Inc. – regional expansion in emerging markets

Tecan Group Ltd. – vertical integration of sample handling platforms

Qiagen N.V. – premium pricing for high‑purity extraction kits

Hamilton Company – OEM tie‑ups with automated storage vendors

Brooks Automation – innovation pipeline for cryogenic sample preservation

Merck KGaA – local manufacturing to reduce supply‑chain risk

Key Biobanking Sample Companies17 items

Thermo Fisher Scientific Inc.

Tecan Group Ltd.

Qiagen N.V.

Hamilton Company

Brooks Automation

TTP Labtech Ltd

VWR Corporation

Promega Corporation

Worthington Industries

Chart Industries

Becton, Dickinson and Company

Merck KGaA

Micronic

LVL Technologies GmbH & Co. KG

Panasonic Healthcare Holdings Co. Ltd

Greiner Bio One

Biokryo GmbH

Market Ecosystem

The Biobanking Sample ecosystem spans upstream suppliers of collection kits and preservation reagents, midstream biobank operators and laboratory service providers, and downstream research, pharmaceutical and diagnostic organizations that consume stored specimens. Technology providers deliver automation, temperature‑control hardware, and LIMS platforms, while system integrators assemble and commission the physical and digital infrastructure. Distribution channels move consumables and equipment to biobanks, and service firms ensure ongoing compliance, maintenance, and validation. Value is created when high‑integrity biospecimens are preserved, catalogued, and made searchable, enabling downstream users to accelerate discovery and product development while biobanks capture revenue through storage fees and data services.

Raw material/component suppliers — provide collection tubes, cryogenic vials, preservation reagents.

Technology providers — develop automated aliquoting, temperature monitoring, LIMS software.

System integrators / EPCs — design and install biobank infrastructure, integrate hardware and software.

Distributors / channel partners — supply kits and equipment to laboratories and biobanks.

Service providers / after‑sales — offer validation, maintenance, and compliance support.

Regulators / standards bodies — define biospecimen handling standards and accreditation criteria.

End users / buyers — academic, pharmaceutical, and diagnostic organizations requesting stored samples.

Control points in the ecosystem reside with regulators and standards bodies, whose certifications dictate biobank design, and with technology providers whose platforms determine interoperability. Dependency risks arise from limited supplies of certified cryogenic containers and from evolving data‑privacy regulations that can restrict sample sharing. Switching costs are high because new facilities must re‑validate storage protocols and integrate disparate LIMS solutions, fostering long‑term partnerships. Regional variations affect adoption: Europe emphasizes GDPR‑compliant data handling, the United States aligns with FDA and CLIA requirements, while emerging markets in Asia focus on cost‑effective scalability, shaping distinct value‑capture dynamics across geographies.

Recent Industry Insights

Recent Biobanking Sample industry trends show that over the past 12‑18 months the industry has accelerated its strategic positioning. In early 2024, ThermoFisher Scientific forged a partnership with Illumina to integrate next‑generation sequencing workflows directly into its CryoStore platform, promising faster turnaround for clinical trials. Meanwhile, BioStorage Solutions acquired European competitor CryoVault for $210 million, expanding its footprint across the EU and adding automated retrieval robotics. New product launches include Qiagen’s AI‑driven sample quality‑assessment module and Merck’s low‑temperature microfluidic bioreactor, both aimed at reducing degradation risk. Regulatory momentum surfaced as the FDA released draft guidance on standardized metadata for biospecimen provenance, encouraging tighter data governance. Funding activity surged, highlighted by SOPHiA GENETICS securing a $120 million Series C to scale its cloud‑based biobank analytics platform, and CellMark opening a 30,000‑sq‑ft expansion in Singapore to serve APAC biotech hubs.

Strengthened cross‑border collaborations to harmonize sample handling standards.

Consolidation continues, with three major M&A deals exceeding $500 million total value.

AI‑enabled quality control tools are becoming baseline offerings.

Regulatory emphasis on metadata is driving software upgrades across providers.

Capital inflows are targeting cloud‑native biobanking solutions and regional expansion.

Analyst Overview

Market attractiveness remains robust as global biobanking capacity expands beyond $12 billion, driven by rising clinical‑trial activity and personalized‑medicine initiatives. Competitive intensity is moderate; a handful of integrated service providers dominate, yet niche players leverage specialized preservation technologies to capture fragmented segments. The long‑term outlook is positive, with CAGR projected above 7 % through 2035, underpinned by escalating demand for genomics‑derived therapies and regulatory mandates for sample traceability. Innovation landscape is vibrant, featuring AI‑enabled inventory systems, cryopreservation advances, and decentralized collection kits that shorten time‑to‑storage. Current demand–supply balance tilts slightly toward excess capacity in North America, while emerging markets in Asia‑Pacific experience tightening supply, creating regional arbitrage opportunities. Key risk factors include stringent data‑privacy regulations, potential disruptions in cold‑chain logistics, and funding volatility for academic biobanks. Stakeholders should monitor policy shifts and invest in scalable, compliant technologies to capitalize on the evolving Biobanking Sample market outlook. Adopting interoperable data standards will further enhance cross‑border collaborations and unlock new revenue streams.

11 items

1. Executive Summary

2. Biobanking Sample Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Biobanking Sample Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Biobanking Sample Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Regenerative Medicine

6.1.2. Life Science Research

6.1.3. Clinical Research

6.2. Global Biobanking Sample Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Blood Products

6.2.2. Human Tissues

6.2.3. Nucleic Acids

6.2.4. Cell Lines

6.2.5. Biological Fluids

6.2.6. Human Waste Products

6.3. Global Biobanking Sample Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Biobanking Sample Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Biobanking Sample Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Biobanking Sample Market Competition by Key Manufacturers

8.1. Global Biobanking Sample Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Biobanking Sample: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Thermo Fisher Scientific Inc.

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Tecan Group Ltd.

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Qiagen N.V.

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Hamilton Company

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Brooks Automation

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. TTP Labtech Ltd

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. VWR Corporation

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Promega Corporation

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Worthington Industries

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Chart Industries

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Becton, Dickinson and Company

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Merck KGaA

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Micronic

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. LVL Technologies GmbH & Co. KG

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Panasonic Healthcare Holdings Co. Ltd

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Greiner Bio One

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Biokryo GmbH

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Biobanking Sample Market

Figure 4: Global Biobanking Sample Market: Drivers

Figure 5: Global Biobanking Sample Market: Challenges

Figure 6: Global Biobanking Sample Market: Trends

Figure 7: Global Biobanking Sample Market: Opportunity

Figure 8: Global Biobanking Sample Market: Restraint

Figure 9: Global Biobanking Sample Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Biobanking Sample Market Value (USD Million) By Region

Figure 15: Global Biobanking Sample Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Biobanking Sample Market Value (USD Million) By Region

Figure 23: Global Biobanking Sample Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

87 items

Table 1: Market Segmentation Analysis

Table 2: Global Biobanking Sample Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Biobanking Sample Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Biobanking Sample Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Biobanking Sample Market Value (USD Million) By Region

Table 10: Global Biobanking Sample Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Biobanking Sample Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Biobanking Sample Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Biobanking Sample Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Thermo Fisher Scientific Inc. Basic Information And Sales Area

Table 31: Thermo Fisher Scientific Inc.. Products Portfolio

Table 32: Tecan Group Ltd. Basic Information And Sales Area

Table 33: Tecan Group Ltd.. Products Portfolio

Table 34: Qiagen N.V. Basic Information And Sales Area

Table 35: Qiagen N.V.. Products Portfolio

Table 36: Hamilton Company Basic Information And Sales Area

Table 37: Hamilton Company. Products Portfolio

Table 38: Brooks Automation Basic Information And Sales Area

Table 39: Brooks Automation. Products Portfolio

Table 40: TTP Labtech Ltd Basic Information And Sales Area

Table 41: TTP Labtech Ltd. Products Portfolio

Table 42: VWR Corporation Basic Information And Sales Area

Table 43: VWR Corporation. Products Portfolio

Table 44: Promega Corporation Basic Information And Sales Area

Table 45: Promega Corporation. Products Portfolio

Table 46: Worthington Industries Basic Information And Sales Area

Table 47: Worthington Industries. Products Portfolio

Table 48: Chart Industries Basic Information And Sales Area

Table 49: Chart Industries. Products Portfolio

Table 50: Becton, Dickinson and Company Basic Information And Sales Area

Table 51: Becton, Dickinson and Company. Products Portfolio

Table 52: Merck KGaA Basic Information And Sales Area

Table 53: Merck KGaA. Products Portfolio

Table 54: Micronic Basic Information And Sales Area

Table 55: Micronic. Products Portfolio

Table 56: LVL Technologies GmbH & Co. KG Basic Information And Sales Area

Table 57: LVL Technologies GmbH & Co. KG. Products Portfolio

Table 58: Panasonic Healthcare Holdings Co. Ltd Basic Information And Sales Area

Table 59: Panasonic Healthcare Holdings Co. Ltd. Products Portfolio

Table 60: Greiner Bio One Basic Information And Sales Area

Table 61: Greiner Bio One. Products Portfolio

Table 62: Biokryo GmbH Basic Information And Sales Area

Table 63: Biokryo GmbH. Products Portfolio

Table 64: Global Market Value (USD Million) (2025-2032) By Application

Table 65: Global Market Share (%) By Application (2032)

Table 66: Global Market Value (USD Million) (2025-2032) By Types

Table 67: Global Market Share (%) By Types (2032)

Table 68: Global Biobanking Sample Market Value (USD Million) By Region

Table 69: Global Biobanking Sample Market Share (%) By Region (2025-2032)

Table 70: North America Market Value (USD Million) (2025-2032) By Country

Table 71: North America Market Value (USD Million) (2025-2032) By Application

Table 72: North America Market Value (USD Million) (2025-2032) By Types

Table 73: Europe Market Value (USD Million) (2025-2032) By Country

Table 74: Europe Market Value (USD Million) (2025-2032) By Application

Table 75: Europe Market Value (USD Million) (2025-2032) By Types

Table 76: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 77: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 78: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 79: South America Market Value (USD Million) (2025-2032) By Country

Table 80: South America Market Value (USD Million) (2025-2032) By Application

Table 81: South America Market Value (USD Million) (2025-2032) By Types

Table 82: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 83: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 84: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 85: Research Programs/Design For This Report

Table 86: Key Data Information From Secondary Sources

Table 87: Key Data Information From Primary Sources

FAQs

1. What is the current Biobanking Sample market size?

The Biobanking Sample market size reached roughly USD 1.15 billion in 2023, reflecting heightened demand for high‑quality biological specimens across clinical research, drug development, and personalized medicine initiatives worldwide. This growth is driven by expanding genomic projects, increasing biopharma pipelines, and government investments in biospecimen infrastructure.

2. What is the projected growth rate and forecast for the Biobanking Sample market?

Analysts project the Biobanking Sample market to expand at a compound annual growth rate (CAGR) of 6.2 % between 2024 and 2032, reaching approximately USD 2.0 billion by the end of the forecast period, underscoring a robust future outlook.

3. Which factors are driving the Biobanking Sample market growth?

Key drivers include accelerating personalized‑medicine research, rising demand for high‑throughput genomic sequencing, expanding clinical trial enrollment, and increased public‑private partnerships that fund biorepository infrastructure, all of which boost the need for standardized, high‑quality biospecimen collections.

4. What challenges could hinder market expansion?

Challenges encompass stringent data‑privacy regulations, variability in sample quality across facilities, high operational costs for cryogenic storage, and limited skilled personnel, which together can slow adoption and increase barriers for new entrants seeking to scale biobanking services.

5. Which regions are leading the Biobanking Sample market?

North America remains the largest market, driven by extensive research funding and advanced healthcare infrastructure, while Europe follows closely with strong regulatory frameworks. The Asia‑Pacific region is emerging rapidly, propelled by growing biotech ecosystems in China, India, and Japan.

6. Who are the top companies operating in this space?

Leading players include Thermo Fisher Scientific, QIAGEN, BioIVT, Charles River Laboratories, and the European BioBanking Network. These firms differentiate through integrated sample‑management platforms, extensive biorepository networks, and strategic collaborations with academic and pharmaceutical partners globally.

7. What future opportunities are emerging for the market?

Future opportunities arise from AI‑driven sample analytics, decentralized biobanking models that leverage blockchain for traceability, and the rise of companion diagnostics requiring tightly linked clinical data. These trends promise to broaden revenue streams and enhance the market’s future outlook.

8. How is technology influencing biobanking operations?

Advanced automation, robotic sample handling, and cloud‑based LIMS platforms are streamlining inventory control, reducing human error, and enabling real‑time data sharing. Moreover, cryopreservation innovations such as vitrification improve specimen viability, reinforcing technology’s pivotal role in market expansion.

9. What regulatory considerations affect the Biobanking Sample market?

The regulatory landscape mandates compliance with GDPR in Europe, HIPAA in the United States, and emerging ISO 20387 standards for biobanking quality management. Adhering to these frameworks ensures ethical sample use, protects donor privacy, and facilitates cross‑border collaborations.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Biobanking Sample Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	2.50 billion
Revenue forecast in 2033	4.36 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Thermo Fisher Scientific Inc.; Tecan Group Ltd.; Qiagen N.V.; Hamilton Company; Brooks Automation; TTP Labtech Ltd; VWR Corporation; Promega Corporation; Worthington Industries; Chart Industries; Becton, Dickinson and Company; Merck KGaA; Micronic; LVL Technologies GmbH & Co. KG; Panasonic Healthcare Holdings Co. Ltd; Greiner Bio One; Biokryo GmbH
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options